Evidence map›Paper›PMID 41658618›Full record

ArticleFrontiers in medicine2026

Impact of lotilaner ophthalmic solution 0.25% on disease severity in patients with

Bridgitte Shen Lee, Elizabeth Yeu, Kavita Dhamdhere, Eric D Donnenfeld

Abstract read
In one paragraph

Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Bridgitte Shen LeeVision Optique, Houston, TX, United States.
Elizabeth YeuTarsus Pharmaceuticals, Inc., Irvine, CA, United States.
Kavita DhamdhereTarsus Pharmaceuticals, Inc., Irvine, CA, United States.
Eric D DonnenfeldOphthalmic Consultants of Long Island, Long Island, NY, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To evaluate the impact of lotilaner ophthalmic solution, 0.25%, compared to vehicle, on disease severity in patients with Methods: This post-hoc analysis pooled data from two prospective, randomized, double-masked studies evaluating lotilaner ophthalmic solution, 0.25% (Ersa, Results: At baseline, meibomian gland disease severity was comparable between groups. At Day 43, 47% of lotilaner-treated patients achieved Grade ≤2 (mild or better), significantly greater than 21% of vehicle-treated patients ( Conclusion: Lotilaner ophthalmic solution, 0.25% significantly improved meibomian gland disease severity in patients with

Indexed as

Demodex blepharitis with meibomian gland diseaselotilanermeibomian gland disease severitymeibomian gland secretion scoreocular surface disease

Identifiers

PMID41658618
PMCPMC12878148

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.